Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% mo

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conf

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71%

Don't catch a falling knife.

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season i

Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with

Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on posi

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing

Recursion Pharmaceuticals (NASDAQ: RXRX) is using artificial intelligence to generate and analyze bi

Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biol

Cramer likes Vistra and Constellation, but not NextEra. Recursion and Fastly reported weak earnings,

California State Teachers Retirement System lifted its holdings in Recursion Pharmaceuticals, Inc. (

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Trans

Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch g

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth chall

Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, se

Recursion Pharmaceuticals NASDAQ: RXRX outlined progress across its clinical pipeline, drug-discover

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed

Genentech advanced the collaboration's first neuroscience target into a joint early discovery progra

Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-s

Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de

ARK's 2025 winners included Robinhood, AMD and Palantir, while its losers were The Trade Desk, R

Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby,

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshapi

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 milli

Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically impro

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective an

Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TL

Several stocks in the health care technology space are moving higher after the market close on Thurs